**Appendices**

**Table A1.** Number of Covid19 and non-Covid-19 articles from 100 medical related journals with the high impact factors and received-accepted dates submitted during 2017-2020 used for this study.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Journal (JCR rank) | Non-Covid-19 articles 2017 | Non-Covid-19 articles 2018 | Non-Covid-19 articles 2019 | Non-Covid-19 articles 2020 | Covid-19 articles 2020 | **Total** |
| Lancet (5) | 152 | 187 | 149 | 94 | 47 | **629** |
| Nature (14) | 860 | 923 | 842 | 421 | 90 | **3,136** |
| Science (15) | 761 | 695 | 685 | 452 | 108 | **2,701** |
| Cell (21) | 445 | 421 | 337 | 151 | 93 | **1,447** |
| Nat Med (23) | 145 | 163 | 155 | 75 | 57 | **595** |
| Lancet Resp Med (57) | 45 | 67 | 63 | 37 | 27 | **239** |
| Lancet Infect Dis (59) | 82 | 110 | 107 | 36 | 50 | **385** |
| Eur Heart J (62) | 179 | 208 | 166 | 98 | 25 | **676** |
| Immunity (65) | 141 | 137 | 109 | 63 | 29 | **479** |
| Lancet Glob Health (67) | 97 | 112 | 99 | 58 | 25 | **391** |
| J Am Coll Cardiol (79) | 247 | 278 | 241 | 210 | 18 | **994** |
| Nat Immunol (82) | 117 | 112 | 104 | 48 | 16 | **397** |
| Gut (88) | 131 | 140 | 162 | 173 | 27 | **633** |
| Blood (103) | 405 | 394 | 405 | 271 | 17 | **1,492** |
| Intens Care Med (104) | 37 | 102 | 81 | 28 | 22 | **270** |
| Gastroenterology (109) | 256 | 251 | 219 | 125 | 16 | **867** |
| Sci Transl Med (128) | 218 | 260 | 281 | 129 | 24 | **912** |
| Lancet Public Health (129) | 36 | 44 | 44 | 30 | 26 | **180** |
| Lancet Psychiat (132) | 46 | 44 | 46 | 32 | 13 | **181** |
| Ann Rheum Dis (134) | 194 | 157 | 143 | 155 | 22 | **671** |
| Diabetes Care (136) | 190 | 198 | 288 | 217 | 25 | **918** |
| Nat Microbiol (142) | 117 | 165 | 106 | 58 | 16 | **462** |
| Sci Immunol (194) | 60 | 79 | 73 | 55 | 24 | **291** |
| Eur Respir J (219) | 211 | 223 | 230 | 114 | 27 | **805** |
| J Clin Invest (237) | 335 | 275 | 368 | 214 | 37 | **1,229** |
| J Exp Med (239) | 178 | 185 | 169 | 136 | 16 | **684** |
| Eur J Heart Fail (242) | 103 | 102 | 152 | 107 | 14 | **478** |
| Med Image Anal (261) | 119 | 152 | 195 | 157 | 14 | **637** |
| Thorax (276) | 99 | 109 | 120 | 119 | 33 | **480** |
| Genome Med (283) | 67 | 61 | 86 | 101 | 15 | **330** |
| Plos Med (291) | 164 | 174 | 261 | 146 | 33 | **778** |
| J Allergy Clin Immun (307) | 242 | 213 | 224 | 194 | 46 | **919** |
| J Am Soc Nephrol (357) | 165 | 170 | 171 | 89 | 23 | **618** |
| Neurology (393) | 498 | 551 | 505 | 227 | 31 | **1,812** |
| Allergy (397) | 5 | 113 | 129 | 137 | 22 | **406** |
| Clin Gastroenterol H (409) | 326 | 349 | 343 | 204 | 16 | **1,238** |
| Lancet Child Adolesc (410) | 22 | 50 | 44 | 28 | 13 | **157** |
| Ophthalmology (413) | 191 | 159 | 129 | 138 | 15 | **632** |
| Chest (430) | 252 | 243 | 223 | 102 | 39 | **859** |
| J Am Acad Dermatol (437) | 319 | 302 | 305 | 343 | 18 | **1,287** |
| J Aller Cl Imm Pract (511) | 192 | 204 | 264 | 291 | 43 | **994** |
| Eur J Cancer (549) | 286 | 267 | 259 | 283 | 28 | **1,123** |
| Eur J Epidemiol (570) | 111 | 70 | 82 | 51 | 22 | **336** |
| Clin Microbiol Infec (571) | 181 | 164 | 161 | 100 | 89 | **695** |
| J Travel Med (579) | 32 | 23 | 23 | 29 | 18 | **125** |
| Eur J Nucl Med Mol I (581) | 199 | 221 | 288 | 246 | 34 | **988** |
| Plos Biol (583) | 215 | 347 | 310 | 183 | 40 | **1,095** |
| B World Health Organ (609) | 53 | 85 | 61 | 21 | 31 | **251** |
| Mayo Clin Proc (610) | 119 | 143 | 95 | 64 | 37 | **458** |
| Gastrointest Endosc (618) | 268 | 232 | 317 | 207 | 18 | **1,042** |
| Bmc Med (637) | 174 | 164 | 175 | 225 | 70 | **808** |
| J Clin Immunol (638) | 56 | 65 | 76 | 83 | 17 | **297** |
| Brain Behav Immun (662) | 239 | 244 | 247 | 276 | 34 | **1,040** |
| Clin Pharmacol Ther (677) | 181 | 144 | 203 | 185 | 25 | **738** |
| Am J Obstet Gynecol (688) | 242 | 213 | 157 | 108 | 30 | **750** |
| Clin Transl Immunol (699) | 9 | 9 | 45 | 78 | 21 | **162** |
| Crit Care (709) | 179 | 185 | 199 | 172 | 73 | **808** |
| Clin Nutr (717) | 260 | 331 | 301 | 364 | 15 | **1,271** |
| Plos Pathog (744) | 535 | 471 | 514 | 503 | 84 | **2,107** |
| Metabolism (761) | 138 | 72 | 124 | 114 | 16 | **464** |
| Cancers (767) | 49 | 397 | 1,563 | 2,745 | 61 | **4,815** |
| Med J Australia (773) | 199 | 94 | 45 | 35 | 16 | **389** |
| Diabetes Obes Metab (829) | 243 | 314 | 221 | 266 | 15 | **1,059** |
| J Clin Microbiol (830) | 275 | 267 | 252 | 197 | 99 | **1,090** |
| Pharmacol Res (832) | 110 | 132 | 176 | 242 | 21 | **681** |
| Brit J Cancer (867) | 406 | 274 | 368 | 236 | 13 | **1,297** |
| Cancer Am Cancer Soc (873) | 430 | 355 | 403 | 349 | 19 | **1,556** |
| Ebiomedicine (885) | 273 | 462 | 480 | 271 | 48 | **1,534** |
| Npj Vaccines (895) | 35 | 42 | 63 | 73 | 27 | **240** |
| Brit J Surg (903) | 165 | 174 | 172 | 96 | 20 | **627** |
| J Int Aids Soc (932) | 103 | 134 | 138 | 85 | 16 | **476** |
| Brit J Haematol (950) | 175 | 214 | 283 | 254 | 17 | **943** |
| Clin Res Cardiol (1047) | 100 | 155 | 133 | 123 | 17 | **528** |
| Can J Cardiol (1063) | 141 | 186 | 196 | 132 | 36 | **691** |
| Heart (1068) | 153 | 143 | 150 | 159 | 16 | **621** |
| Front Immunol (1119) | 1,620 | 2,170 | 1,802 | 2,271 | 163 | **8,026** |
| J Med Internet Res (1144) | 348 | 439 | 655 | 549 | 299 | **2,290** |
| J Infect Dis (1154) | 353 | 427 | 398 | 181 | 109 | **1,468** |
| Ann Allerg Asthma Im (1178) | 213 | 151 | 115 | 133 | 25 | **637** |
| Blood Adv (1211) | 303 | 367 | 408 | 536 | 25 | **1,639** |
| J Immunol (1224) | 685 | 610 | 579 | 396 | 22 | **2,292** |
| Front Oncol (1251) | 153 | 491 | 1,346 | 2,535 | 40 | **4,565** |
| J Infection (1256) | 121 | 90 | 103 | 73 | 63 | **450** |
| Aging (1264) | 107 | 363 | 1,204 | 1,464 | 110 | **3,248** |
| Int J Hyg Envir Heal (1282) | 115 | 105 | 146 | 127 | 14 | **507** |
| Pediat Allerg Imm (1345) | 3 | 61 | 85 | 125 | 18 | **292** |
| J Gen Intern Med (1423) | 199 | 296 | 333 | 280 | 70 | **1,178** |
| J Am Coll Surgeons (1425) | 198 | 151 | 59 | 62 | 30 | **500** |
| Travel Med Infect Di (1426) | 77 | 61 | 60 | 32 | 45 | **275** |
| J Virol (1476) | 789 | 790 | 729 | 425 | 96 | **2,829** |
| Am J Prev Med (1536) | 244 | 236 | 252 | 171 | 31 | **934** |
| J Am Med Dir Assoc (1577) | 183 | 234 | 225 | 249 | 60 | **951** |
| Bmj Glob Health (1641) | 164 | 195 | 218 | 204 | 54 | **835** |
| Diabetes Res Clin Pr (1672) | 273 | 271 | 272 | 267 | 79 | **1,162** |
| Brit J Gen Pract (1709) | 103 | 95 | 108 | 53 | 17 | **376** |
| J Am Geriatr Soc (1721) | 46 | 272 | 312 | 276 | 63 | **969** |
| Antivir Res (1788) | 208 | 181 | 184 | 95 | 43 | **711** |
| J Adolescent Health (1952) | 214 | 219 | 257 | 170 | 45 | **905** |
| Int Immunopharmacol (1954) | 383 | 544 | 694 | 796 | 57 | **2,474** |
| Resp Res (1971) | 165 | 232 | 286 | 216 | 45 | **944** |
| **Total** | **22,050** | **24,726** | **27,933** | **26,104** | **4,038** | **104,851** |

**Table A2.** Main topics, document types, and research types of Covid-19 articles from 30 selected medical related journals with high impact factors and with 10 or less days of review process (n=49 articles).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Journal (JCR Rank)** | **Dur. of Review (days)** | **Scopus citation** | **Title** | **Main Covid-19 topic** | **Document Type** | **Type of research** |
| Lancet (5) | 7 | 3406 | A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. | Infection, transmission or control | Article | Clinical observation |
| Lancet (5) | 4 | 1480 | Clinical characteristics and intrauterine vertical transmission potential of Covid-19 infection in nine pregnant women: a retrospective review of medical records. | Infection, transmission or control | Article | Clinical case report |
| Lancet (5) | 2 | 14854 | Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. | Infection, transmission or control | Article | Clinical observation |
| Lancet (5) | 5 | 7189 | Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. | Infection, transmission or control | Article | Clinical observation |
| Lancet (5) | 4 | 174 | First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. | Infection, transmission or control | Article | Clinical case report |
| Lancet (5) | 5 | 3944 | Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. | Genomic structure | Article | Laboratory |
| Lancet (5) | 10 | 225 | Investigation of three clusters of Covid-19 in Singapore: implications for surveillance and response measures. | Infection, transmission or control | Article | Clinical observation |
| Lancet (5) | 3 | 1478 | Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. | Infection, transmission or control | Article | Epidemiological Modelling |
| Lancet (5) | 9 | 319 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. | Vaccines | Article | Clinical Trial |
| Lancet (5) | 10 | 161 | Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost Covid-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. | Vaccines | Article | Clinical Trial |
| Lancet (5) | 6 | 448 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. | Vaccines | Article | Clinical Trial |
| Lancet (5) | 10 | 389 | Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored Covid-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. | Vaccines | Article | Clinical Trial |
| Lancet (5) | 9 | 11 | Voluntary collective isolation as a best response to Covid-19 for indigenous populations? A case study and protocol from the Bolivian Amazon. | Infection, transmission or control | Practice guideline | Practice guideline development |
| Nature (14) | 9 | 6180 | A pneumonia outbreak associated with a new coronavirus of probable bat origin. | Genomic structure | Article | Laboratory |
| Science (15) | 7 | 10 | Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. | Genomic structure | Article | Laboratory |
| Cell (21) | 7 | 2166 | Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. | Genomic structure | Article | Laboratory |
| Nat Med (23) | 7 | 30 | Modeling Covid-19 scenarios for the United States. | Infection, transmission or control | Article | Epidemiological Modelling |
| Lancet Resp Med (57) | 4 | 3380 | Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. | Infection, transmission or control | Article | Clinical observation |
| Lancet Infect Dis (59) | 10 | 991 | Estimates of the severity of coronavirus disease 2019: a model-based analysis. | Infection, transmission or control | Article | Epidemiological Modelling |
| Lancet Infect Dis (59) | 10 | 1181 | Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. | Infection, transmission or control | Article | Clinical observation |
| Lancet Glob Health (67) | 1 | 775 | Feasibility of controlling Covid-19 outbreaks by isolation of cases and contacts. | Infection, transmission or control | Article | Epidemiological Modelling |
| J Am Coll Cardiol (79) | 8 | 37 | High thrombus burden in patients with Covid-19 presenting with st-segment elevation myocardial infarction. | Infection, transmission or control | Article | Clinical observation |
| Gut (88) | 5 | 11 | Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the Covid-19 pandemic: a RAND appropriateness panel. | Infection, transmission or control | Article | Survey |
| Gut (88) | 9 | 98 | British Society of Gastroenterology guidance for management of inflammatory bowel disease during the Covid-19 pandemic. | Infection, transmission or control | Practice guideline | Practice guideline development |
| Gut (88) | 2 | 29 | Famotidine use and quantitative symptom tracking for Covid-19 in non-hospitalised patients: a case series. | Infection, transmission or control | Article | Clinical observation |
| Gut (88) | 6 | 10 | One world, one pandemic, many guidelines: management of liver diseases during Covid-19. | Infection, transmission or control | Practice guideline | Practice guideline development |
| Gut (88) | 6 | 110 | Outcomes of Covid-19 in 79 patients with IBD in Italy: an IG-IBD study. | Infection, transmission or control | Article | Clinical observation |
| Gut (88) | 3 | 136 | Practice of endoscopy during Covid-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-Covid statements). | Infection, transmission or control | Practice guideline | Practice guideline development |
| Blood (103) | 7 | 37 | ILROG emergency guidelines for radiation therapy of hematological malignancies during the Covid-19 pandemic. | Infection, transmission or control | Practice guideline | Practice guideline development |
| Intens Care Med (104) | 9 | 805 | High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. | Infection, transmission or control | Article | Clinical observation |
| Intens Care Med (104) | 5 | 632 | Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (Covid-19). | Infection, transmission or control | Practice guideline | Practice guideline development |
| Gastroenterology (109) | 10 | 175 | Alterations in gut microbiota of patients with Covid-19 during time of hospitalization. | Infection, transmission or control | Article | Clinical observation |
| Gastroenterology (109) | 10 | 409 | Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. | Infection, transmission or control | Article | Clinical observation |
| Gastroenterology (109) | 4 | 44 | Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of Covid-19. | Infection, transmission or control | Brief Communications | Clinical observation |
| Gastroenterology (109) | 7 | 84 | Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: A multicenter cohort study. | Infection, transmission or control | Brief Communications | Clinical observation |
| Gastroenterology (109) | 3 | 72 | Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome coronavirus 2 outbreak in Northern Italy. | Infection, transmission or control | Article | Clinical observation |
| Lancet Public Health (129) | 9 | 602 | The effect of control strategies to reduce social mixing on outcomes of the Covid-19 epidemic in Wuhan, China: a modelling study. | Infection, transmission or control | Article | Epidemiological Modelling |
| Lancet Psychiat (132) | 9 | 245 | Neurological and neuropsychiatric complications of Covid-19 in 153 patients: a UK-wide surveillance study. | Infection, transmission or control | Article | Clinical observation |
| Ann Rheum Dis (134) | 7 | 263 | Characteristics associated with hospitalisation for Covid-19 in people with rheumatic disease: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. | Infection, transmission or control | Article | Clinical observation |
| Diabetes Care (136) | - | 26 | Diabetes and Covid-19: Risks, Management, and Learnings From Other National Disasters. | Infection, transmission or control | Practice guideline | Practice guideline development |
| Diabetes Care (136) | 1 | 16 | Diabetes Epidemiology in the Covid-19 Pandemic. | Infection, transmission or control | Practice guideline | Practice guideline development |
| Diabetes Care (136) | 2 | 36 | Issues of cardiovascular risk management in people with diabetes in the Covid-19 era. | Infection, transmission or control | Practice guideline | Practice guideline development |
| Diabetes Care (136) | 3 | 14 | Saving the Diabetic Foot During the Covid-19 Pandemic: A Tale of Two Cities. | Infection, transmission or control | Article | Clinical case report |
| Nat Microbiol (142) | 8 | 829 | Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. | Genomic structure | Article | Clinical case report |
| Sci Immunol (194) | 3 | 135 | Comprehensive mapping of immune perturbations associated with severe Covid-19. | Infection, transmission or control | Article | Clinical case report |
| Sci Immunol (194) | 8 | 101 | Inhibition of Bruton tyrosine kinase in patients with severe Covid-19. | Infection, transmission or control | Article | Clinical case report |
| Eur Respir J (219) | 2 | 14 | Covid-19: guidance on palliative care from a European Respiratory Society international task force. | Infection, transmission or control | Practice guideline | Clinical case report |
| Ophthalmology (413) | 10 | 18 | Symptomatic Covid-19 in Eye Professionals in Wuhan, China. | Infection, transmission or control | Article | Survey |
| Eur J Heart Fail (242) | 3 | 2 | SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. | Infection, transmission or control | Brief Communications | Clinical case report |

Figure B1. Average (geometric mean) days of review processes and 95% confidence intervals for Covid-19 and other articles in medical related journals 51-100 with high impact factors submitted during 2019-2020.

Figure B2. Spearman correlations between the duration of review processes and Scopus citations to Covid-19 and non-Covid-19 articles in medical related journals 51-100 with high impact factors submitted during 2019-2020.

Figure B3. Average (geometric mean) days of publication processes (measured by days between submission and addition to PubMed) and 95% confidence intervals for Covid-19 and other articles in medical related journals 51-100 with high impact factors submitted during 2019-2020.

Figure B4. Average (geometric mean) days of publication processes (measured by days between submission and addition to PubMed) and 95% confidence intervals for Covid-19 and other articles in medical related journals 51-100 with high impact factors submitted during 2019-2020.